Department of Internal Medicine I - Division of Oncology,
Comprehensive Cancer Center,
Department of Internal Medicine I - Division of Oncology, Comprehensive Cancer Center
Michael Krainer has not added Biography.
If you are Michael Krainer and would like to personalize this page please email our Author Liaison for assistance.
Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival.
Cancer Dec, 2005 | Pubmed ID: 16270321
Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance.
The Prostate Mar, 2007 | Pubmed ID: 17192910
A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
The Journal of urology Jun, 2007 | Pubmed ID: 17509302
Linking the ovarian cancer transcriptome and immunome.
BMC systems biology Jan, 2008 | Pubmed ID: 18173842
BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF-beta treatment.
Gynecologic oncology May, 2010 | Pubmed ID: 20189233
The role of c-FLIP(L) in ovarian cancer: chaperoning tumor cells from immunosurveillance and increasing their invasive potential.
Gynecologic oncology Jun, 2010 | Pubmed ID: 20227749
Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer.
Molecular cancer therapeutics Apr, 2010 | Pubmed ID: 20371719
Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients.
BMC cancer Dec, 2010 | Pubmed ID: 21129172
Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression.
Cancer Mar, 2011 | Pubmed ID: 21381010
hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research Dec, 2011 | Pubmed ID: 22016507
TUSC3 loss alters the ER stress response and accelerates prostate cancer growth in vivo.
Scientific reports Jan, 2014 | Pubmed ID: 24435307
Circulating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker study.
PloS one , 2014 | Pubmed ID: 24755958
The potential evasion of immune surveillance in mucosa associated lymphoid tissue lymphoma by DcR2-mediated up-regulation of nuclear factor-κB.
Leukemia & lymphoma May, 2015 | Pubmed ID: 25248880
HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells.
Molecular cancer research : MCR Mar, 2015 | Pubmed ID: 25349289
Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.
BMC cancer Dec, 2014 | Pubmed ID: 25523155
Tumor suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition and inhibits tumor growth by modulating the endoplasmic reticulum stress response in ovarian cancer cells.
International journal of cancer Sep, 2015 | Pubmed ID: 25735931
The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma.
PloS one , 2015 | Pubmed ID: 26248232
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 09, 2016 | Pubmed ID: 27400947
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna.
ESMO open , 2016 | Pubmed ID: 27843624
Increased genitourinary fistula rate after bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and image-guided adaptive brachytherapy.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] Dec, 2017 | Pubmed ID: 28721510
The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna.
ESMO open , 2017 | Pubmed ID: 28761758
Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells.
Oncotarget Jan, 2018 | Pubmed ID: 29416657
Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.
European journal of cancer (Oxford, England : 1990) 07, 2018 | Pubmed ID: 29636272
Analysis of hematological parameters as prognostic markers for toxicity and survival of Radium treatment.
Oncotarget Mar, 2018 | Pubmed ID: 29662636
LUBAC and ABIN-1 Modulate TRAIL-Based NF-κB Induction in Human Embryonic Kidney 293 Cells.
BioResearch open access , 2018 | Pubmed ID: 29862142
Synthetic lethal combinations of low-toxicity drugs for breast cancer identified by genetic screens in yeast.
Oncotarget Nov, 2018 | Pubmed ID: 30555636
Synthetic lethality guiding selection of drug combinations in ovarian cancer.
PloS one , 2019 | Pubmed ID: 30682083
Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
European urology oncology 12, 2018 | Pubmed ID: 31158090
Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia.
Prostate cancer and prostatic diseases 06, 2020 | Pubmed ID: 31745255
Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database.
European journal of cancer (Oxford, England : 1990) 01, 2020 | Pubmed ID: 31787484
Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer.
Cancers Feb, 2020 | Pubmed ID: 32120793
Corrigendum to "Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database" [Eur J Canc 125, (January 2020) 153-163].
European journal of cancer (Oxford, England : 1990) Sep, 2020 | Pubmed ID: 32605716
Erratum to 'Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database' [European Journal of Cancer, Volume 125 (January 2020) Pages 153-163].
European journal of cancer (Oxford, England : 1990) Sep, 2020 | Pubmed ID: 32723589
Impact of frailty on the management of patients with gynecological cancer aged 80 years and older.
Archives of gynecology and obstetrics 02, 2021 | Pubmed ID: 33009994
Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field.
ESMO open 10, 2020 | Pubmed ID: 33051192
Loss of HCRP1 leads to upregulation of PD-L1 via STAT3 activation and is of prognostic significance in EGFR-dependent cancer.
Translational research : the journal of laboratory and clinical medicine Apr, 2021 | Pubmed ID: 33197651
JoVE Hakkında
Telif Hakkı © 2020 MyJove Corporation. Tüm hakları saklıdır